6.03
+0.025(+0.42%)
Currency In USD
| Previous Close | 6.01 |
| Open | 6 |
| Day High | 6.1 |
| Day Low | 5.95 |
| 52-Week High | 75 |
| 52-Week Low | 5.74 |
| Volume | 33,155 |
| Average Volume | 43,928 |
| Market Cap | 11.22M |
| PE | -0.45 |
| EPS | -13.3 |
| Moving Average 50 Days | 9.28 |
| Moving Average 200 Days | 15.92 |
| Change | 0.03 |
If you invested $1000 in BioVie Inc. (BIVI) since IPO date, it would be worth $6.04 as of August 02, 2025 at a share price of $6.03. Whereas If you bought $1000 worth of BioVie Inc. (BIVI) shares 3 years ago, it would be worth $28.31 as of August 02, 2025 at a share price of $6.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
GlobeNewswire Inc.
Jul 24, 2025 12:00 PM GMT
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of agingCARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a cli
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
GlobeNewswire Inc.
Jul 22, 2025 12:00 PM GMT
Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s missionCARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”),
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advance